K., "Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior antitumour

Size: px
Start display at page:

Download "K., "Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior antitumour"

Transcription

1 University of Massachusetts Medical School Rheumatology Publications and Presentations Rheumatology Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study Josef S. Smolen Medical University Vienna Jonathan Kay University of Massachusetts Medical School Worcester Eric L. Matteson Mayo Clinic See next page for additional authors Follow this and additional works at: Part of the Musculoskeletal Diseases Commons, Rheumatology Commons, and the Skin and Connective Tissue Diseases Commons Repository Citation Smolen, Josef S.; Kay, Jonathan; Matteson, Eric L.; Landewe, Robert; Hsia, Elizabeth C.; Xu, Stephen; Zhou, Yiying; and Doyle, Mittie K., "Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior antitumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study" (2014). Rheumatology Publications and Presentations This material is brought to you by It has been accepted for inclusion in Rheumatology Publications and Presentations by an authorized administrator of For more information, please contact

2 Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study Authors Josef S. Smolen, Jonathan Kay, Eric L. Matteson, Robert Landewe, Elizabeth C. Hsia, Stephen Xu, Yiying Zhou, and Mittie K. Doyle Keywords golimumab, methotrexate, rheumatoid arthritis Creative Commons License This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License This article is available at escholarship@umms:

3 EXTENDED REPORT Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study Josef S Smolen, 1 Jonathan Kay, 2 Eric L Matteson, 3 Robert Landewé, 4 Elizabeth C Hsia, 5,6 Stephen Xu, 7 Yiying Zhou, 7 Mittie K Doyle 8 Handling editor Tore K Kvien For numbered affiliations see end of article. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Medical University of Vienna and Department of Medicine III, Hietzing Hospital, Waehringer Guertel 18-20, Vienna A-1090, Austria; josef.smolen@wienkav.at Received 7 February 2013 Revised 14 May 2013 Accepted 29 June 2013 Published Online First 29 July 2013 Open Access Scan to access more free content To cite: Smolen JS, Kay J, Matteson EL, et al. Ann Rheum Dis 2014;73: ABSTRACT Objective Evaluate golimumab in patients with active rheumatoid arthritis (RA) and previous tumour necrosis factor-α (TNF) inhibitor use. Methods Patients (n=461) previously receiving 1 TNF inhibitor were randomised to subcutaneous injections of placebo, golimumab 50 mg or golimumab 100 mg q4 weeks. Primary endpoint ( 20% improvement in American College of Rheumatology (ACR20) criteria at week 14) findings have been reported for all patients in the trial. Reported herein are further assessments of efficacy/safety among patients receiving golimumab +methotrexate (MTX). Results Among efficacy-evaluable patients who received MTX at baseline, more receiving golimumab +MTX (n=201) than placebo+mtx (n=103) achieved ACR20 (40.8% vs 14.6%), ACR50 (20.9% vs 3.9%), and ACR70 (11.4% vs 2.9%) responses at week 24. Among the 137 patients who had received only one prior TNF inhibitor (adalimumab, n=33; etanercept, n=47; and infliximab, n=57), week 24 ACR20 rates were 30.3%, 46.8% and 50.9%, respectively, and thus lowest among those who previously used adalimumab. ACR20 response rates were 44.5% (61/137), 36.2% (17/47) and 23.5% (4/17) among patients who had received one, two or three TNF inhibitors, respectively. Adverse event (AE) rates were comparable across type/ number of prior anti-tnf agents, but appeared somewhat higher among patients who discontinued previous TNF inhibitor(s) due to intolerance (37/49, 75.5%) versus lack of efficacy (LOE, 113/191, 59.2%). Conclusions Patients with active RA previously treated with 1 TNF inhibitor had clinically relevant improvement with golimumab+mtx, which appeared somewhat enhanced among those who received only etanercept or infliximab as their prior TNF inhibitor. Golimumab+MTX safety appeared similar across patients, regardless of TNF inhibitor(s) previously used, with fewer AEs occurring among patients who discontinued prior therapy for LOE. More than a decade has passed since the initial introduction of tumour necrosis factor-α (TNF) inhibitors, which have greatly expanded treatment options for patients with rheumatoid arthritis (RA). 1 Given that patients may not always respond to the first TNF inhibitor prescribed and that there is long-term experience with using other TNF inhibitors, it is reasonable to assume that, in line with recent disease management recommendations, 2 3 clinicians will be treating increasing numbers of patients exposed previously to one or more TNF inhibitor(s). Results of several small case series, open-label studies and registries have indicated that patients who switched from one TNF inhibitor to another resulting from lack of efficacy or intolerance may respond to a second or even third TNF inhibitor. 4 9 Benefits of switching from etanercept to infliximab, and vice versa, have been investigated Additionally, the strategy of switching patients with RA who are inadequately responsive to a TNF inhibitor to a biological agent with a different mode of action has been compared with that of switching to another TNF inhibitor in nonrandomised observational studies of data from registries. 615 To date, the results of several randomised controlled trials (RCTs) investigating therapies targeted against molecules other than TNF in patients with RA who failed TNF-blockade have been published However, the GO-AFTER trial evaluated the efficacy of TNF inhibitor therapy after prior TNF inhibitor use in an RCT. 20 In the GO-AFTER trial, not all patients were receiving concomitant methotrexate (MTX), and the primary clinical endpoint was evaluated at 14 weeks because of ethical considerations, although secondary clinical and co-primary functional endpoints were assessed at 6 months in all patients. 20 Some RCTs of biological therapies for patients with RA with prior TNF inhibitor use have typically studied the biological agent in combination with MTX and assessed primary endpoints at 6 months Some, but not all, 23 systematic reviews may not have considered differences in trial design when evaluating studies. Because some authors have suggested that switching to another monoclonal antibody rather than to an anti-tnf receptor construct agent may be more efficacious after anti-tnf failure, 15 especially if the prior TNF inhibitor was discontinued due to lack of efficacy, 24 more detailed information on response rates to Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

4 golimumab in patients who had previously received different TNF inhibitors would inform the selection of candidates for golimumab therapy. To assess and compare the efficacy and safety of golimumab following discontinuation of one or more other TNF inhibitors in a subgroup of patients and at a time point comparable to those of most other RCTs of biological RA therapies, we examined GO-AFTER trial data from a novel perspective. We present the findings of post-hoc analyses of data obtained from patients with active RA previously treated with one or more TNF inhibitor and also receiving MTX after 6 months of study drug treatment in that trial, as well as hypotheses for assessment in future studies. METHODS Patients As detailed previously, 20 eligible patients had RA for 3 months prior to screening and active disease with 4 swollen and 4 tender joints (mean values: 16.6/66 and 29.8/68, respectively). Patients had received one or more doses of etanercept, adalimumab or infliximab 8 (adalimumab, etanercept) or 12 (infliximab) weeks prior to receiving the first dose of study agent. Patients must not have had a clinically serious adverse reaction to any of the prior anti-tnf agents. Previous anti-tnf treatment could have been discontinued for any reason, and the reason(s) for discontinuation were documented by the investigator as either lack of efficacy, intolerance or other. Procedures Patients were randomised (1:1:1) to receive subcutaneous placebo, golimumab 50 mg or golimumab 100 mg every 4 weeks. Randomisation was stratified by investigational site and baseline MTX use (yes/no). Patients and investigators were masked to study treatment assignment; golimumab and placebo were supplied in identical single-use vials. Concomitant MTX use was permitted, but not required, if continued at a stable dose. Patients in the placebo and golimumab 50-mg groups with <20% improvement in both tender and swollen joint counts at week 16 escaped early to receive golimumab 50 mg and 100 mg, respectively, at week 16 and week 20. Study medication was not altered in the 100-mg group. Week 24 was the efficacy time point of interest in these post-hoc analyses. Clinical response was assessed using the American College of Rheumatology (ACR) criteria indicating 20%, 50% and/or 70% (ACR20, 25 ACR50 and ACR70) improvement, as well as by achievement of a good or moderate response according to the 28-joint Disease Activity Score (DAS28) and/or DAS28 < DAS28 was determined using C reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Physical function was assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI), 28 and a functional response was defined as 0.25-unit improvement 29 from baseline to week 24. Safety was evaluated by reviewing documentation of reported adverse events (AEs). Data analysis Prior anti-tnf therapy was summarised using descriptive statistics by reason for discontinuation and by duration of prior TNF inhibitor for patients who had taken only one prior TNF inhibitor. Since patients could have received more than one TNF inhibitor, the numbers of patients who had discontinued their prior TNF inhibitor were also summarised by reason for discontinuation using non-mutually exclusive prior TNF inhibitor cessation categories. Efficacy analyses were performed using patients randomised to receive golimumab who reported concomitant MTX use at baseline (n=205). Efficacy data from one North American site were excluded from these analyses because of protocol violations identified during the Sponsor s standard audit processes, yielding 201 efficacy-evaluable patients. Clinical outcomes by prior anti-tnf treatment were summarised using descriptive statistics for randomised patients. The proportions of patients achieving ACR20 and ACR50 responses, DAS28-CRP and DAS28-ESR responses, DAS28-CRP and DAS28-ESR each <2.6, and HAQ DI response at week 24 were determined among patients who previously had received only one anti-tnf agent and discontinued the treatment for any reason. Clinical response was similarly assessed among patients who had discontinued prior anti-tnf therapy as a result of lack of efficacy, because of intolerance, or for other reasons, as well as among patients based on the number of previous TNF inhibitors received. For patients who escaped early, efficacy data from week 16 were carried forward for analysis at week 24 to ensure that the results were not biased by the increased dose of golimumab that the patient received at week 16 or week Summaries of AEs include only treated patients (n=204). Data from patients who were treated at the site that was excluded from efficacy analyses are included in these safety summaries. The overall incidences of AEs are summarised by prior anti-tnf agent, as well as by the number of anti-tnf agents received previously and by the reason(s) for discontinuation of prior anti-tnf therapy. RESULTS Disposition of prior anti-tnf therapy In the GO-AFTER trial, 461 patients were randomly assigned to receive placebo (n=155), golimumab 50 mg (n=153) or golimumab 100 mg (n=153) every 4 weeks. 20 Baseline characteristics for the MTX-treated subgroup of randomised patients (table 1) were generally consistent with those of the overall study population, 20 although fewer MTX-treated patients tested positive for rheumatoid factor at baseline than did patients with no MTX use at baseline (table 1). With the exception of shorter disease duration (8.5 vs 11.6 years, respectively; p=0.023) and more women patients (90.9% (30/33) vs 70.2% (40/57), respectively; p=0.023) among adalimumab-only versus infliximab-only-treated patients, no consistent baseline differences were observed across prior TNF inhibitors (data not shown). Without the 16 patients treated at the excluded site, 445 randomised patients were available for efficacy analyses, 304 of whom were also receiving MTX at baseline. Two hundred and one of them were randomised to golimumab and were also receiving MTX (table 2); much smaller proportions of patients were receiving sulfasalazine (4.9%) and/or hydrochloroquine (7.4%) in addition to MTX. Among the efficacy-evaluable golimumab-randomised patients who were also receiving MTX, 137 had previously received only one TNF inhibitor (adalimumab, n=33; etanercept, n=47; and infliximab, n=57). For each prior TNF inhibitor, the proportion of patients who discontinued that agent because of lack of efficacy was 2.5-fold to 11-fold greater than those who discontinued because of intolerance (table 1). Overall, most patients received prior anti-tnf therapy for 24 weeks (table 1). Clinical improvement All golimumab-randomised patients who were receiving MTX at baseline Among patients with active RA who were previously treated with a TNF inhibitor, 40.8% of golimumab+mtx-treated 1812 Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

5 Table 1 baseline Summary of baseline characteristics* in randomised patients and previous TNF inhibitor use among patients receiving MTX at MTX use at baseline No MTX use at baseline Placebo Golimumab Placebo Golimumab Randomised patients*, n Women 89 (83.2%) 160 (78.0%) 43 (89.6%) 75 (74.3%) Age years 54.8± ± ± ±11.07 Disease duration years 12.4± ± ± ±9.19 Swollen joint count (0 66) 17.0± ± ± ±12.12 Tender joint count (0 68) 29.8± ± ± ±17.85 Rheumatoid factor positive 69 (67.0%) 137 (69.5%) 41 (85.4%) 76 (77.6%) HAQ-DI (0 3) 1.6± ± ± ±0.68 CRP (mg/l) 20.8± ± ± ±33.94 ESR (mm h) 38.9± ± ± ±28.97 DAS28-CRP score 5.7± ± ± ±1.05 DAS28-ESR score 6.3± ± ± ±1.24 Number of Prior TNF inhibitors 1 TNF inhibitor 2 TNF inhibitors 3 TNF inhibitors Golimumab-randomised MTX-treated patients, n Prior TNF inhibitor Adalimumab only Etanercept only Infliximab only Golimumab-randomised patients who received only one prior TNF inhibitor,n Reason for discontinuation of prior TNF inhibitor Lack of efficacy 22 (66.7%) 23 (48.9%) 22 (38.6%) Intolerance 5 (15.2%) 2 (4.3%) 8 (14.0%) Other reason 6 (18.2%) 22 (46.8%) 27 (47.4%) Distribution by duration of prior treatment, n <4 weeks to <12 weeks to <24 weeks to <36 weeks to <48 weeks weeks % patients receiving therapy for 24 weeks 48.5% 57.4% 82.5% Data presented are number (%) of patients or mean±sd unless otherwise noted. *Baseline characteristics are summarised for all randomised patients with available data. Efficacy-related patient subgroups exclude patients from a single site due to violations at the study site identified during the Sponsor s standard audit processes. In the vast majority of patients, the other reason for discontinuation of previous anti-tnf agent(s) was related to cost/insurance coverage. CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; TNF, tumour necrosis factor. patients and 14.6% of placebo+mtx-treated patients achieved an ACR20 response at week 24. The ACR50 and ACR70 response rates were also higher among patients who received golimumab+mtx (20.9% and 11.4%, respectively) than among those who received placebo+mtx (3.9% and 2.9%, respectively). Similar patterns of improvement were observed when disease activity was assessed using the DAS28-CRP or the DAS28-ESR and also when using achievement of a 0.25-unit reduction in the HAQ-DI score to assess improvement in physical function (table 2). All golimumab-randomised patients who were receiving MTX at baseline and who had discontinued only one prior TNF inhibitor Among efficacy-evaluable, golimumab-randomised patients receiving MTX at baseline, 137 had previously received only one prior TNF inhibitor (adalimumab, n=33; etanercept, n=47; infliximab, n=57). The proportion of patients who achieved an ACR20 response at week 24 was 30.3% among those who previously had been treated only with adalimumab, 46.8% among those who previously had been treated only with etanercept and 50.9% among those who previously had been treated only with infliximab. A similar pattern of clinical response was observed when ACR50 response criteria were applied (figure 1). Also at week 24, the proportions of patients achieving DAS28-CRP response (good/moderate) and DAS28-CRP <2.6 were 39.4% and 15.2%, respectively, among those who previously had been treated only with adalimumab, 61.7% and 14.9%, respectively, among those who previously had been treated only with etanercept and 66.7% and 17.5%, respectively, among those who previously had been treated only with infliximab. Similar patterns were observed for DAS28-ESR response (good/moderate) and DAS28-ESR<2.6 (figure 1). Improvement in physical function, as assessed by achievement of a 0.25-unit reduction in the HAQ-DI score from baseline to week 24, was fairly consistent across the three TNF inhibitors used previously and was achieved by 48.5%, 53.2% and 56.1% of patients who had received only adalimumab, etanercept or infliximab, respectively (figure 1). Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

6 Clinical and epidemiological research Table 2 Summary of clinical efficacy at week 24* among efficacy-evaluable randomised patients receiving MTX at baseline Golimumab Efficacy-evaluable randomised patients receiving study agent+mtx, n ACR20 response ACR50 response ACR70 response DAS28-CRP response DAS28-CRP score <2.6 DAS28-ESR response DAS28-ESR score <2.6 HAQ-DI 0.25-unit improvement Placebo 50 mg 100 mg Combined (14.6%) 4 (3.9%) 3 (2.9%) 24 (23.3%) 2 (1.9%) 27 (26.2%) 1 (1.0%) 35 (34.0%) 36 (35.6%) 20 (19.8%) 12 (11.9%) 49 (48.5%) 12 (11.9%) 49 (48.5%) 11 (10.9%) 48 (47.5%) 46 (46.0%) 22 (22.0%) 11 (11.0%) 65 (65.0%) 14 (14.0%) 67 (67.0%) 16 (16.0%) 54 (54.0%) 82 (40.8%) 42 (20.9%) 23 (11.4%) 114 (56.7%) 26 (12.9%) 116 (57.7%) 27 (13.4%) 102 (50.7%) Data presented are number (%) of patients unless otherwise noted. *For patients who early escaped, efficacy data from week 16 were carried forward for analysis at week 24. Excludes patients from a single site due to violations at the study site identified during the Sponsor s standard audit processes. These violations were not confirmed until after the initial publication of trial results, thus resulting in minor numerical differences in response rates between the initial report20 and the current paper regarding patients treated with golimumab+mtx. DAS28-CRP/ESR score indicating a good or moderate response. ACR20, ACR 50, ACR70, at least 20%, 50%, or 70% improvement according to the American College of Rheumatology response criteria; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate. Figure 1 Improvement in rheumatoid arthritis signs and symptoms and physical function in golimumab-randomised patients with baseline methotrexate use by reason for discontinuations of prior TNF inhibitor use, including any reason (A), lack of efficacy (B), intolerance (C) and other reasons (D). ACR20, ACR50, at least 20% or 50% improvement according to the American College of Rheumatology response criteria; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index response ( 0.25-unit improvement); TNF, tumour necrosis factor Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

7 Among patients who discontinued prior TNF inhibitor treatment because of lack of efficacy, ACR20 response rates at week 24 were 36.4% for those who previously had been treated only with adalimumab, 56.5% for those who previously had been treated only with etanercept and 45.5% for those who previously had been treated only with infliximab. Among patients who discontinued previous TNF inhibitor treatment because of intolerance, ACR20 response rates at week 24 were 20.0%, 50.0% and 62.5% for adalimumab, etanercept and infliximab, respectively, but sample sizes were small. Similarly, among those who discontinued previous TNF inhibitor treatment for other reasons, respective ACR20 response rates at week 24 were 16.7%, 36.4% and 51.9% for adalimumab, etanercept and infliximab, respectively (figure 1). In table 3, clinical responses at week 24 are compared by the number of TNF inhibitors that patients had received prior to study entry. By most measures, improvement in clinical signs and symptoms and in physical function appeared to be more robust among patients who previously had received fewer TNF inhibitors. However, the numbers of patients who had received two (n=47) and three (n=17) prior TNF inhibitors were limited. Adverse events Safety findings for all patients enrolled in the GO-AFTER study have been reported through week and also through up to 3 years of golimumab therapy. 30 AEs were reported by 64.3% of all MTX-treated patients. Among these, 75.5% of patients who had been intolerant of prior therapy and 59.2% of those who had an inadequate response to treatment with the prior TNF inhibitor(s) reported AEs. The overall proportions of patients developing AEs were similar among those treated with either golimumab or placebo, when grouped by number of prior TNF inhibitors received, specific prior TNF inhibitor received or reason for discontinuation of that previous agent (table 4). Table 3 Clinical response at week 24* among golimumab+ MTX-treated patients by number of previous TNF inhibitor(s) Number of previous TNF inhibitor(s) 1 TNF inhibitor 2 TNF inhibitors 3 TNF inhibitors Patients who discontinued one or more previous TNF-inhibitor for any reason, n ACR20 response 61 (44.5%) 17 (36.2%) 4 (23.5%) ACR50 response 30 (21.9%) 11 (23.4%) 1 (5.9%) DAS28 response (good/ moderate) DAS28-CRP 80 (58.4%) 24 (51.1%) 10 (58.8%) DAS28-ESR 82 (59.9%) 24 (51.1%) 10 (58.8%) DAS28 score <2.6 DAS28-CRP 22 (16.1%) 3 (6.4%) 1 (5.9%) DAS28-ESR 23 (16.8%) 3 (6.4%) 1 (5.9%) HAQ-DI 0.25-unit improvement 73 (53.3%) 22 (46.8%) 7 (41.2%) Data presented are number (%) of patients unless otherwise noted. *For patients who escaped early, efficacy data from week 16 were carried forward for analysis at week 24. Excludes patients from a single site due to violations at the study site identified during the Sponsor s standard audit processes. ACR20, ACR50, at least 20% or 50% improvement according to the American College of Rheumatology response criteria; CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; TNF, tumour necrosis factor. The incidences of serious AEs and serious infections appeared to be comparable across the subgroups of patients evaluated, with the exception of a higher incidence of serious AEs among patients who had received three (18.8%) prior TNF inhibitors, compared with those who previously had received one (2.5%) or two (3.8%) TNF inhibitors. However, interpretation of these findings is limited by the small numbers of patients who experienced serious AEs or serious infections (table 4). DISCUSSION Although data derived from several small case series, open-label studies and registries have suggested that patients with RA switched from one to another TNF inhibitor because of lack of efficacy or intolerance may respond to the second or even third agent, 4 9 such response patterns have not previously been examined in a randomised, controlled study. Using data from the GO-AFTER trial, 20 we evaluated the efficacy and safety of golimumab when switching from another TNF inhibitor among more than 200 patients with active RA who previously received adalimumab, etanercept and/or infliximab and reported MTX use at baseline. Our post-hoc data analyses indicate that among patients taking MTX at baseline, the response rates at week 24 are somewhat higher than those reported previously for all patients at the primary endpoint of week This is consistent with the generally accepted principle that concomitant use of MTX with a TNF inhibitor results in better clinical and functional outcomes Moreover, patients who switch from adalimumab, etanercept or infliximab to golimumab demonstrate clinically relevant responses at week 24, regardless of whether the prior TNF inhibitor was a monoclonal antibody or a soluble receptor fusion protein. Of note and consistent with results of a comparative meta-analysis, 23 although it is difficult to compare outcomes across clinical trials due to differences in trial design, week 24 ACR response rates among patients who had discontinued prior anti-tnf therapy and received golimumab+mtx in GO-AFTER are comparable to those observed at the same week 24 time point for other biological agents with different mechanisms of action in combination with MTX. For example, week 24 ACR50 response rates for study agent versus placebo, both with concomitant disease-modifying antirheumatic drugs, were 27% and 5% for rituximab 16 ; 29% (8 mg/kg), 17% (4 mg/kg) and 4% for tocilizumab 34 ; and 20% and 4% for abatacept. 18 The most straightforward approach to assess effects of switching agents is to analyse data derived from patients previously treated with only one prior TNF inhibitor. Despite our previously reported observations of clinically relevant responses to golimumab in the overall trial population, 20 patients previously exposed to more than two TNF inhibitors appear to be less likely to demonstrate marked improvement in clinical and functional outcomes. ACR50 response rates were similar among patients who had been treated with one or two prior TNF inhibitors, but were much lower when golimumab was initiated as the fourth TNF inhibitor. Although these findings suggest that such patients might respond better to a biological agent with a different mechanism of action, it should be considered that the rates of response to each of rituximab and abatacept also decrease with previous exposure to increasing numbers of TNF inhibitors Future studies employing biomarkers may help to predict which patients are more likely to respond to the different agents, following initial exposure to a TNF inhibitor. Because patients were not stratified by prior TNF inhibitor use when randomised to treatment arms, the size of some of the subgroups that were evaluated was small, and our subgroup Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

8 Table 4 MTX-treated patients with adverse events by number, type, and reason for discontinuation of previous TNF inhibitor(s) during the placebo-controlled study period (weeks 0 16) Placebo+MTX Golimumab+MTX All patients All Adverse Events (AEs) 67/107 (62.6%) 133/204 (65.2%) 200/311 (64.3%) All AEs by number of prior agents 1 TNF inhibitor 38/60 (63.3%) 93/140 (66.4%) 131/200 (65.5%) 2 TNF inhibitors 20/33 (60.6%) 28/46 (60.9%) 48/79 (60.8%) 3 TNF inhibitors 9/14 (64.3%) 12/18 (66.7%) 21/32 (65.6%) All AEs by prior agent* Adalimumab only 10/14 (71.4%) 21/34 (61.8%) 31/48 (64.6%) Etanercept only 9/17 (52.9%) 31/49 (63.3%) 40/66 (60.6%) Infliximab only 19/29 (65.5%) 41/57 (71.9%) 60/86 (69.8%) All AEs by reason for d/c of agent Lack of efficacy 40/70 (57.1%) 73/121 (60.3%) 113/191 (59.2%) Intolerance 13/16 (81.3%) 24/33 (72.7%) 37/49 (75.5%) Other reason 24/40 (60.0%) 52/75 (69.3%) 76/115 (66.1%) Serious Adverse Events (SAEs) 8/107 (7.5%) 6/204 (2.9%) 14/311 (4.5%) SAEs by number of prior agents 1 TNF inhibitor 3/60 (5.0%) 2/140 (1.4%) 5/200 (2.5%) 2 TNF inhibitors 2/33 (6.1%) 1/46 (2.2%) 3/79 (3.8%) 3 TNF inhibitors 3/14 (21.4%) 3/18 (16.7%) 6/32 (18.8%) SAEs by prior agent* Adalimumab only 0/14 (0.0%) 2/34 (5.9%) 2/48 (4.2%) Etanercept only 0/17 (0.0%) 0/49 (0.0%) 0/66 (0.0%) Infliximab only 3/29 (10.3%) 0/57 (0.0%) 3/86 (3.5%) SAEs by reason for d/c of agent Lack of efficacy 7/70 (10.0%) 4/121 (3.3%) 11/191 (5.8%) Intolerance 1/16 (6.3%) 2/33 (6.1%) 3/49 (6.1%) Other reason 1/40 (2.5%) 1/75 (1.3%) 2/115 (1.7%) Serious Infections (SIs) 3/107 (2.8%) 2/204 (1.0%) 5/311 (1.6%) SIs by number of prior agents 1 TNF inhibitor 2/60 (3.3%) 1/140 (0.7%) 3/200 (1.5%) 2 TNF inhibitors 1/33 (3.0%) 0/46 (0.0%) 1/79 (1.3%) 3 TNF inhibitors 0/14 (0.0%) 1/18 (5.6%) 1/32 (3.1%) SIs by prior agent* Adalimumab only 0/14 (0.0%) 1/34 (2.9%) 1/48 (2.1%) Etanercept only 0/17 (0.0%) 0/49 (0.0%) 0/66 (0.0%) Infliximab only 2/29 (6.9%) 0/57 (0.0%) 2/86 (2.3%) SIs by reason for d/c of prior agent Lack of efficacy 2/70 (2.9%) 1/121 (0.8%) 3/191 (1.6%) Intolerance 0/16 (0.0%) 1/33 (3.0%) 1/49 (2.0%) Other reason 1/40 (2.5%) 1/75 (1.3%) 2/115 (1.7%) Data presented are number (%) of treated patients. *Among patients who received only one prior TNF inhibitor. Some patients had received more than one TNF inhibitor and could have discontinued each one for a different reason. In the vast majority of patients, the other reason for discontinuation of previous anti-tnf agent(s) was related to cost/insurance coverage. d/c, discontinuation; MTX, methotrexate; TNF, tumour necrosis factor. analyses were performed post-hoc, no formal statistical testing was performed. Despite these limitations, the data reveal numerical trends. For example, ACR20 response rates at week 24 for patients treated with golimumab 50 or 100 mg and MTX were numerically higher among those who switched from etanercept (46.8%) or infliximab (50.9%) compared with those who had previously received adalimumab (30.3%), the agent most similar in structure to golimumab. 37 Conversely, the proportion of patients who were previously treated with adalimumab for more than 24 weeks was much lower than that of patients who had previously received treatment with etanercept or infliximab for more than 24 weeks, which could have been due to a larger number of patients with refractory disease among those receiving adalimumab treatment. It is possible that patients previously treated with agents structurally more dissimilar to golimumab developed antibodies to the prior TNF inhibitor that precluded continued response to the previous agent 38 ; these antibodies might have been less likely to cross-react with the human golimumab molecule, allowing a better subsequent response to golimumab. The presence of antibodies to prior TNF inhibitor(s) was not assessed in GO-AFTER. However, future studies of switching among TNF inhibitors should include such assessments to better characterise the mechanisms underlying differential responses to subsequent treatment. The safety profile of golimumab+mtx was similar to that of placebo+mtx and was consistent among patients who previously received adalimumab, etanercept or infliximab, and among those who had received one, two or three prior TNF inhibitors. When assessed by reason for discontinuation of previous anti-tnf agent(s), however, AEs appeared to be more 1816 Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

9 common among patients who had discontinued prior anti-tnf therapy because of intolerance than because of lack of efficacy or other reasons. The incidences of serious AEs and serious infections were low, but appeared comparable across patient subgroups evaluated, except for a somewhat higher incidence of serious AEs among patients who had received three (18.8%) prior TNF inhibitors, compared with those who previously had received one (2.5%) or two (3.8%) inhibitors. Overall, the safety findings are not unexpected given that TNF inhibitors as a class, regardless of the specific molecular construct, share similar potential safety risks. This post-hoc subgroup analysis has several limitations. As mentioned above, patient randomisation was not stratified by the specific TNF inhibitor or by the number of TNF inhibitors used previously. Subgroup sample size was small in some of these comparisons. Also, patients enrolled into the GO-AFTER trial could have discontinued their prior TNF inhibitor(s) for any reason; reasons for discontinuation were categorised at the discretion of the study investigator, as no formal definitions were provided. In conclusion, patients with active RA who previously received TNF inhibitor therapy and were treated with golimumab and concomitant MTX in the GO-AFTER trial demonstrated clinically relevant improvement in disease activity and physical function after switching to golimumab, regardless of which TNF inhibitor had been taken previously. Of particular note, patients who switched from either etanercept or infliximab appeared to exhibit better subsequent responses to golimumab than those that were observed among patients who previously had received adalimumab which, of the three prior TNF inhibitors, is most structurally similar to golimumab. However, further study is required to confirm the current findings. Author affiliations 1 Division of Rheumatology, Department of Medicine III, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria 2 Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA 3 Division of Rheumatology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA 4 Division of Rheumatology, Academic Medical Center, Amsterdam and Atrium Medical Center, Heerlen, The Netherlands 5 Clinical Immunology, Janssen Research & Development, LLC., Spring House Pennsylvania, USA 6 Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA 7 Biologics Biostatistics, Janssen Research & Development, LLC., Spring House, Pennsylvania, USA 8 Translational Medicine Group, Alexion Pharmaceuticals, Cambridge, Massachusetts, USA Acknowledgements We thank Kirsten Schuck, Michelle Perate, MS, and Mary Whitman, PhD, of Janssen Services, LLC, for their assistance in the development and submission of this manuscript. Funding This study was supported by Janssen Research & Development, LLC and Merck/Schering-Plough. Competing interests JSS, JK, ELM and RL are research investigators for the GO-AFTER golimumab clinical trial. JSS has received research grant support from Abbott, BMS, MSD, Pfizer, Roche and UCB and consultation and/or speaking honoraria from Abbott, Astra-Zeneca, BMS, Celgene, Glaxo, Janssen, MSD, Novo-Nordisk, Pfizer, Roche, Sanofi-Aventis and UCB. JK has received research funding paid to the University of Massachusetts Medical School from Bristol Myers Squibb Co., F. Hoffmann-La Roche Ltd. and Sanofi-Aventis and consulting income from Bristol Myers Squibb Co., Crescendo BioScience Inc., Eisai Co. Ltd., Janssen, Johnson & Johnson, Mallinckrodt Inc., NovoNordisk Inc., Pfizer Inc. and UCB S.A. ELM has received research grant support and consultation honoraria from Janssen. RL has received research grant support from Abbott, Pfizer, Roche and UCB and consultation and/or speaking honoraria from Abbott, Astra-Zeneca, BMS, Glaxo, Janssen, MSD, Pfizer, Roche and UCB. EC Hsia, S Xu, and Y Zhou are employees of Janssen Research & Development, LLC; MKD was employed by Janssen at the time this manuscript was initially drafted and is now employed by Alexion Pharmaceuticals. Ethics approval The GO-AFTER study (ClinicalTrials.gov: NCT ) was conducted according to principles of the Declaration of Helsinki. All patients provided written informed consent, and the protocol was approved by a central and individual institutional review boards. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: licenses/by-nc/3.0/ REFERENCES 1 Hetland ML, Christensen IJ, Tarp U, et al.; on behalf of All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in nationwide Danish DANBIO registry. Arthritis Rheum 2010;62: Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69: Singh JA, Furst D, Bharat A update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64: Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009;11:R Erickson AR, Mikuls TR. Switching anti-tnf-alpha agents: what is the evidence? Curr Rheumatol Rep 2007;9: Gomez-Reino JJ, Carmona L; and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29. 7 Hyrich KL, Lunt M, Watson KD, et al. for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti tumor necrosis factor α agent to a second anti tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56: Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009;61: van Vollenhoven RF. Switching between biological agents. Clin Exp Rheumatol 2004;22(Suppl 35):S Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23: Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007;66: Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31: Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27: van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62: Finckh A, Ciurea A, Brulhart L, et al.; on behalf of the physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti tumor necrosis factor agents. Arthritis Rheum 2007;56: Cohen SB, Emery P, Greenwald MW, et al. for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54: Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

10 anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67: Genovese MC, Becker J-C, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353: Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67: Smolen JS, Kay J, Doyle MK, et al., for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374: Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69: Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009;(4): CD Schoels M, Aletaha D, Smolen JS, et al. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71: Finckh A, Ciurea A, Brulhart L, et al., on behalf of the doctors of the Swiss Clinical Quality Management Programme for Rheumatoid Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-tnf agent? Ann Rheum Dis 2010;69: Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: Prevoo MLL, van t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38: van Riel PLCM, van Gestel AM, Scott DL.; on behalf of The EULAR Standing Committee for International Clinical Studies including Therapeutic Trials ESCISIT. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications B.V., 2000: Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient s perspective. J Rheumatol 1993;20: Smolen JS, Kay J, Landewé RBM, et al. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 2012;71: Breedveld FC, Weisman MH, Kavanaugh AF, et al. for the PREMIER Investigators. the PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54: Klareskog L, van der Heijde D, de Jager JP, et al. for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363: Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-tnf treatment. Rheumatology (Oxford) 2012;51(Suppl 5):v Kremer JM, Tony H, Tak PP, et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006;65 (Suppl II):326 (Abstract FRI0133). Poster session FRI0133 presented at the 7th Annual European Congress of Rheumatology (EULAR 2006), Amsterdam, June Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68: Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117: Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54: Enbrel (Etanercept) Summary of Product Characteristics. European Medicines Agency. (accessed Jan 2013). 40 Humira (Adalimumab) Summary of Product Characteristics. European Medicines Agency. (accessed Jan 2013). 41 Remicade (Infliximab) Summary of Product Characteristics. European Medicines Agency. (accessed Jan 2013) Smolen JS, et al. Ann Rheum Dis 2014;73: doi: /annrheumdis

Abatacept (Orencia) for active rheumatoid arthritis. August 2009

Abatacept (Orencia) for active rheumatoid arthritis. August 2009 Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has

More information

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC

Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine

More information

Pharmacy Medical Necessity Guidelines: Orencia (abatacept)

Pharmacy Medical Necessity Guidelines: Orencia (abatacept) Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or

More information

METHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological

METHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research

More information

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy

More information

Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity 7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense

More information

Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months

Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch

More information

Received: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003

Received: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003 Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders

More information

6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline

6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)

More information

The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis

The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis ARTHRITIS & RHEUMATISM Vol. 63, No. 5, May 2011, pp 1200 1210 DOI 10.1002/art.30263 2011, American College of Rheumatology The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results

More information

Rheumatoid arthritis 2010: Treatment and monitoring

Rheumatoid arthritis 2010: Treatment and monitoring October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes

More information

New Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab

New Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate

More information

Concise report. Additional supplementary data are published online only. To view these fi les please visit the journal online ( bmj.

Concise report. Additional supplementary data are published online only. To view these fi les please visit the journal online (  bmj. Additional supplementary data are published online only. To view these fi les please visit the journal online (http://ard. bmj.com) 1 Department of Rheumatology, University of Colorado School of Medicine,

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our

More information

M Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8

M Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8 The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

More information

M Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8

M Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8 1 University of Colorado, Denver, Colorado, USA; 2 Rheumatology Specialty Center, Willow Grove, Pennsylvania, USA; 3 Arthritis Associates, Hixson, Tennessee, USA; 4 Hospital Universitario Marques De Valdecilla,

More information

New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate

New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits

More information

Introduction ORIGINAL ARTICLE

Introduction ORIGINAL ARTICLE Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda

More information

ORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION

ORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab

More information

Abatacept: first T cell co-stimulation modulator for severe active RA

Abatacept: first T cell co-stimulation modulator for severe active RA Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method

More information

Golimumab: a novel anti-tumor necrosis factor

Golimumab: a novel anti-tumor necrosis factor Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher

More information

Received: 28 November 2007 / Revised: 11 February 2008 / Accepted: 12 February 2008 / Published online: 19 March 2008 # The Author(s) 2008

Received: 28 November 2007 / Revised: 11 February 2008 / Accepted: 12 February 2008 / Published online: 19 March 2008 # The Author(s) 2008 Clin Rheumatol (08) 27:1021 1028 DOI 10.1007/s10067-008-0866-4 ORIGINAL ARTICLE An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab

More information

OPEN ACCESS EXTENDED REPORT. Clinical and epidemiological research

OPEN ACCESS EXTENDED REPORT. Clinical and epidemiological research OPEN ACCESS 1 Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 3 Department

More information

Division of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland 4

Division of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland 4 Original papers Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population Sławomir Jeka 1,A,B,D F, Bogdan

More information

M. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*

M. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2* Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2 2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial

More information

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing

More information

Correspondence should be addressed to Martin J. Bergman;

Correspondence should be addressed to Martin J. Bergman; Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive

More information

CADTH Therapeutic Review Panel

CADTH Therapeutic Review Panel Therapeutic Review Panel Final Recommendations Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 RECOMMENDATIONS The Therapeutic Review Panel (TRP) recommends that in adult

More information

Research Article. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice

Research Article. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice Research Article Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice Aim: To evaluate treatment of rheumatoid arthritis with abatacept in the real-life clinic

More information

This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors..

This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/118272/ Version: Accepted

More information

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs RHEUMATOLOGY Rheumatology 2012;51:v12 v21 doi:10.1093/rheumatology/kes111 Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs Karel

More information

Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients

Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve

More information

(tofacitinib) are met.

(tofacitinib) are met. Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically

More information

G Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report

G Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report 1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA

More information

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis To cite: Fleischmann RM, Huizinga TWJ, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262. doi:10.1136/rmdopen-2016-000262

More information

What I Have Learned Over the Years - Keystone s Top 10 -

What I Have Learned Over the Years - Keystone s Top 10 - What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,

More information

Inflammatory arthritis, such as rheumatoid arthritis (RA), is

Inflammatory arthritis, such as rheumatoid arthritis (RA), is O r i g i n a l A r t i c l e Using Biologics in Inflammatory Arthritis: Assessing the Risks and Benefits Gina Rohekar MD FRCPC MSc (Clin Epi) About the Author Gina Rohekar is an assistant professor at

More information

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable

More information

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic

More information

James R. O Dell, M.D. University of Nebraska Medical Center

James R. O Dell, M.D. University of Nebraska Medical Center Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,

More information

Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195

Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195

More information

Synopsis (C0524T12 GO LIVE)

Synopsis (C0524T12 GO LIVE) Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,

More information

TNF inhibitor therapy for rheumatoid arthritis (Review)

TNF inhibitor therapy for rheumatoid arthritis (Review) BIOMEDICAL REPORTS 1: 177-184, 2013 TNF inhibitor therapy for rheumatoid arthritis (Review) XIXI MA and SHENGQIAN XU Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations

More information

Principal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (

Principal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project ( Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:

More information

PsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.

PsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL. RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright

More information

Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder

Orencia (abatacept) for Rheumatoid Arthritis. Media backgrounder Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a

More information

1 Executive summary. Background

1 Executive summary. Background 1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions

More information

Pharmacy Medical Necessity Guidelines: Actemra (tocilizumab)

Pharmacy Medical Necessity Guidelines: Actemra (tocilizumab) Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical

More information

Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1

Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1 IQWiG Reports Commission No. A10-01 Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1 Executive Summary 1 Translation of the executive summary of the final report Biotechnologisch

More information

Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis

Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle

More information

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

TNF Inhibitors: Lessons From Immunogenicity

TNF Inhibitors: Lessons From Immunogenicity TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:

More information

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry Harrold et al. Arthritis Research & Therapy (2016) 18:280 DOI 10.1186/s13075-016-1179-7 RESEARCH ARTICLE Open Access Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients

More information

The Journal of Rheumatology Volume 41, no. 2

The Journal of Rheumatology Volume 41, no. 2 The Volume 41, no. 2 Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study Edward C. Keystone,

More information

ORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D.

ORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D. Arthritis Care & Research Vol. 63, No. 6, June 2011, pp 856 864 DOI 10.1002/acr.20452 2011, American College of Rheumatology ORIGINAL ARTICLE Greater Likelihood of Remission in Rheumatoid Arthritis Patients

More information

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,

More information

CLINICAL BRIEFS. Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases

CLINICAL BRIEFS. Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases CLINICAL BRIEFS Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases A review of immunogenicity and potential implications By Joseph Flood, MD, FACR President, Musculoskeletal

More information

TITLE: Biologic Switching for Patients with Rheumatoid Arthritis: A Review of Clinical Effectiveness, Safety, and Guidelines

TITLE: Biologic Switching for Patients with Rheumatoid Arthritis: A Review of Clinical Effectiveness, Safety, and Guidelines TITLE: Biologic Switching for Patients with Rheumatoid Arthritis: A Review of Clinical Effectiveness, Safety, and Guidelines DATE: 14 December 2015 CONTEXT AND POLICY ISSUES Rheumatoid arthritis (RA) is

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA) Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs Thank you for agreeing to give us a statement on your organisation's view

More information

Charité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3

Charité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3 Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis

Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis

More information

golimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s

golimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s Module 5.3.5.1 Rheumatoid Arthritis IV (24-Week submission) 24-Week CNTO148ART3001Clinical Study Report SYNOPSIS Issue Date: 07 Nov 2011 Document No.: EDMS-ERI-22836553 Name of Sponsor/Company Name of

More information

Bringing the clinical experience with anakinra to the patient

Bringing the clinical experience with anakinra to the patient Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen

More information

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises

More information

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research

More information

RAISE Rheumatoid Arthritis Independent Swiss Treatment Expectations and Outcome: results for the abatacept subpopulation

RAISE Rheumatoid Arthritis Independent Swiss Treatment Expectations and Outcome: results for the abatacept subpopulation Published 6 December 2013, doi:10.4414/smw.2013.13849 Cite this as: RAISE Rheumatoid Arthritis Independent Swiss Treatment Expectations and Outcome: results for the abatacept subpopulation Jean Dudler

More information

SYNOPSIS. Issue Date: 17 Jan 2013

SYNOPSIS. Issue Date: 17 Jan 2013 STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &

More information

Research Article. Robin Christensen* 1,2, Simon Tarp 1, Daniel E Furst 3, Lars E Kristensen 1,4 & Henning Bliddal 1

Research Article. Robin Christensen* 1,2, Simon Tarp 1, Daniel E Furst 3, Lars E Kristensen 1,4 & Henning Bliddal 1 Research Article Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST AMPLE network randomized trial Our objective was to assess the efficacy

More information

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab)

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Effective: November 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical

More information

Dose optimization of infliximab in patients with rheumatoid arthritis

Dose optimization of infliximab in patients with rheumatoid arthritis International Journal of Rheumatic Diseases 2014; 17: 5 18 REVIEW ARTICLE Dose optimization of infliximab in patients with rheumatoid arthritis Rieke ALTEN 1 and Filip VAN DEN BOSCH 2 1 Department of Internal

More information

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis Clin Rheumatol (2008) 27:1343 1353 DOI 10.1007/s10067-008-0964-3 REVIEW ARTICLE Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis Andrew J K Östör Received: 18 June

More information

Pharmacy Medical Necessity Guidelines:

Pharmacy Medical Necessity Guidelines: Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Original article RHEUMATOLOGY

Original article RHEUMATOLOGY RHEUMATOLOGY Rheumatology 2015;54:2188 2197 doi:10.1093/rheumatology/kev249 Advance Access publication 21 July 2015 Original article Final 10-year effectiveness and safety results from study DE020: adalimumab

More information

Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?

Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient? Mian et al. Arthritis Research & Therapy (2016) 18:142 DOI 10.1186/s13075-016-1028-8 RESEARCH ARTICLE Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction

More information

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Handling editor Tore K Kvien 1 Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching

More information

Criteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or

Criteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,

More information

What does it mean for Pharmacists?

What does it mean for Pharmacists? 18th Congress of the European Association of Hospital Pharmacists (EAHP) Paris, 14 March 2013 What does it mean for Pharmacists? Value-based Decision Making in Rheumatic Disease Pr. REES France 28, Rue

More information

Comments from Wyeth on the Assessment Report for the appraisal of Enbrel in RA General Comments

Comments from Wyeth on the Assessment Report for the appraisal of Enbrel in RA General Comments General Comments The TAR economic model is a complex model that attempts to reflect the multiple treatment options and pathways an RA patient can follow. This model demonstrates that it would be cost effective

More information

intolerance to tumour necrosis

intolerance to tumour necrosis To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic

More information

ABSTRACT ORIGINAL RESEARCH

ABSTRACT ORIGINAL RESEARCH https://doi.org/10.1007/s40744-018-0113-7 ORIGINAL RESEARCH Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan

More information

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Certolizumab pegol (Cimzia) for psoriatic arthritis second line Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA; Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate

More information

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;

Extended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA; 1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &

More information

Technology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375

Technology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology

More information

ABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH

ABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH Rheumatol Ther (2018) 5:149 158 https://doi.org/10.1007/s40744-018-0094-6 ORIGINAL RESEARCH Maintenance of Remission with Etanercept DMARD Combination Therapy Compared with DMARDs Alone in African and

More information

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial Handling editor Tore K Kvien For numbered affiliations see end of article. Correspondence to Dr Michael Schiff, University of Colorado, School of Medicine, 5400 South Monaco Street, Greenwood Village,

More information

Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)

Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion

More information

Primary Results Citation 2

Primary Results Citation 2 Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical

More information

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition The new england journal of medicine original article Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition Mark C. Genovese, M.D., Jean-Claude Becker, M.D., Michael Schiff,

More information